Novartis Nears $1.7B Avidity Biosciences Acquisition
Swiss pharmaceutical giant Novartis AG is finalizing a landmark acquisition of California-based Avidity Biosciences in a deal valuing the biotech firm at over $70 per share, potentially exceeding $1.7 billion, according to exclusive reports.